Patric Stenberg is the founder of Gesynta Pharma. Gesynta Pharma has raised $67M in total funding. Latest round: Series B. Based in Stockholm, Sweden.
Patric Stenberg is the CEO of Gesynta Pharma, a company developing vipoglanstat, a novel non-hormonal drug candidate for the treatment of endometriosis. Gesynta Pharma recently secured SEK 304 million in a Series B financing round to advance vipoglanstat towards being Phase III-ready, with a focus on a European Phase II clinical trial.
Full founder directory · Investor directory · Company funding database · Fundraising library